Literature DB >> 26905274

Advances in the Management of Anal Cancer.

Diana R Julie1, Karyn A Goodman2.   

Abstract

Although anal squamous cell carcinoma (ASCC) is an uncommon malignancy, its incidence has been increasing markedly in recent decades due to its association with human papilloma virus (HPV) infection. The well-established standard of care for localized ASCC consists of the combination of 5-fluorouracil (5FU) and mitomycin (MMC) chemotherapy, concurrent with external beam radiation therapy (EBRT). However, newer techniques are being actively pursued, including the use of newer radiation therapy (RT) technologies, such as intensity-modulated radiation therapy (IMRT). The areas of debate and development include the dosing and timing of MMC delivery, the role of cisplatin chemotherapy as an alternative to MMC, the replacement of the standard 96-h infusion of 5FU with oral capecitabine, the use of targeted chemotherapy agents, and the duration and dose of RT.

Entities:  

Keywords:  Anal cancer; Definitive chemoradiation; Human papilloma virus; Intensity-modulated radiotherapy; Squamous cell carcinoma

Mesh：

Substances：

Year:  2016        PMID： 26905274     DOI： 10.1007/s11912-016-0503-3

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  71 in total

1.  Practice parameters for anal squamous neoplasms.

Authors:  Phillip R Fleshner; Sridhar Chalasani; George J Chang; David H Levien; Neil H Hyman; W Donald Buie
Journal:  Dis Colon Rectum       Date:  2007-11-21       Impact factor: 4.585

2.  Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.

Authors: 
Journal:  Lancet       Date:  1996-10-19       Impact factor: 79.321

3.  Results of salvage abdominoperineal resection for recurrent anal carcinoma following combined chemoradiation therapy.

Authors:  B C van der Wal; B I Cleffken; B Gulec; H S Kaufman; M A Choti
Journal:  J Gastrointest Surg       Date:  2001 Jul-Aug       Impact factor: 3.452

Review 4.  Anal squamous cell carcinoma: an evolution in disease and management.

Authors:  Marc C Osborne; Justin Maykel; Eric K Johnson; Scott R Steele
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

5.  Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal.

Authors:  Kim Huang; Daphne Haas-Kogan; Vivian Weinberg; Richard Krieg
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

6.  Understanding the burden of human papillomavirus-associated anal cancers in the US.

Authors:  Djenaba A Joseph; Jacqueline W Miller; Xiaocheng Wu; Vivien W Chen; Cyllene R Morris; Marc T Goodman; Jose M Villalon-Gomez; Melanie A Williams; Rosemary D Cress
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

7.  Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C.

Authors:  B J Cummings; T J Keane; B O'Sullivan; C S Wong; C N Catton
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-10       Impact factor: 7.038

8.  Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.

Authors:  Jaffer A Ajani; Kathryn A Winter; Leonard L Gunderson; John Pedersen; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher Willett
Journal:  JAMA       Date:  2008-04-23       Impact factor: 56.272

9.  Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients.

Authors:  Joachim Widder; Reinhard Kastenberger; Elisabeth Fercher; Rainer Schmid; Johannes A Langendijk; Werner Dobrowsky; Richard Pötter
Journal:  Radiother Oncol       Date:  2008-05-22       Impact factor: 6.280

10.  Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis.

Authors:  Tina Dasgupta; Diana Rothenstein; Joanne F Chou; Zhigang Zhang; Jean L Wright; Leonard B Saltz; Larissa K Temple; Philip B Paty; Martin R Weiser; Jose G Guillem; Garrett M Nash; Karyn A Goodman
Journal:  Radiother Oncol       Date:  2013-05-18       Impact factor: 6.280
View more
  6 in total

1.  Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).

Authors:  Stefano Kim; Marine Jary; Thierry André; Véronique Vendrely; Bruno Buecher; Eric François; François-Clément Bidard; Sarah Dumont; Emmanuelle Samalin; Didier Peiffert; Simon Pernot; Nabil Baba-Hamed; Farid El Hajbi; Olivier Bouché; Jérôme Desrame; Aurélie Parzy; Mustapha Zoubir; Christophe Louvet; Jean-Baptiste Bachet; Thierry Nguyen; Meher Ben Abdelghani; Denis Smith; Christelle De La Fouchardière; Thomas Aparicio; Jaafar Bennouna; Jean-Marc Gornet; Marion Jacquin; Franck Bonnetain; Christophe Borg
Journal:  BMC Cancer       Date:  2017-08-25       Impact factor: 4.430

2.  Construction and validation of a prognostic nomogram for anal squamous cell carcinoma.

Authors:  Ningning Yang; Lu Xu; Qingqing Wang; Fengxia Chen; Yunfeng Zhou
Journal:  Cancer Med       Date:  2021-12-01       Impact factor: 4.452

3.  Survival rate variation with different histological subtypes of poor prognostic male anal squamous cell carcinoma: a population-based study.

Authors:  Zihao Wan; Zhihao Huang; Vikash Vikash; Kelash Rai; Sindhu Vikash; Liaobin Chen; Jingfeng Li
Journal:  Oncotarget       Date:  2017-09-16

4.  Patterns of care for anal cancer in the United States - a comparison between academic and community cancer centers.

Authors:  Victor E Pricolo; Matteo Bonvini; Carlo F Abelli
Journal:  BMC Cancer       Date:  2018-05-16       Impact factor: 4.430

Review 5.  Recent advances in the management of anal cancer.

Authors:  Matthew M Symer; Heather L Yeo
Journal:  F1000Res       Date:  2018-09-28

6.  Combined PET-CT and MRI for response evaluation in patients with squamous cell anal carcinoma treated with curative-intent chemoradiotherapy.

Authors:  Pratik Adusumilli; Noha Elsayed; Stelios Theophanous; Robert Samuel; Rachel Cooper; Nathalie Casanova; Damien J Tolan; Alexandra Gilbert; Andrew F Scarsbrook
Journal:  Eur Radiol       Date:  2022-03-11       Impact factor: 7.034
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.